US corporate hopes to break Swiss franc market's silence
Amgen, the US multinational bio-pharmaceutical company, on Monday announced plans for its debut bond in Swiss francs, a transaction that bankers hope could turn a gloomy February market around.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: